TITLE

Creabilis Reports Positive Phase IIb Data for Itch Drug

AUTHOR(S)
Moran, Nuala
PUB. DATE
May 2013
SOURCE
BioWorld Today;5/13/2013, Vol. 24 Issue 91, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents the report of biotechnology firm Creabilis SA based in London, England on results of Phase llb for its topical TrkA kinase inhibitor CT327 for relief of chronic pruritus caused by psoriasis. It discusses findings which on the efficacy of CT327 based on the modified Psoriasis Area and Severity Index. Comment from Eliot Forster, Chief Executive Officer (CEO) of Creabilis, is presented.
ACCESSION #
87593101

 

Related Articles

  • Creabilis Reports Positive Phase IIb Data for Itch Drug. Moran, Nuala // BioWorld International;5/15/2013, Vol. 18 Issue 20, p2 

    The article reports a positive Phase 2b trial results for Creabilis SA's topical TrkA kinase inhibitor CT327 for the relief of chronic pruritus caused by psoriasis. It notes that patients who received CT327 had a significant and meaningful reduction in pruritus of 60% as compared to 20% for...

  • Creabilis Raises $20M in Series B to Advance Psoriasis Drug. Sheridan, Cormac // BioWorld International;10/5/2011, Vol. 16 Issue 40, p1 

    The article reports on a Series B financing round completed by Creabilis SA in 2011. Proceeds will be used on the development of a psoriasis drug. Details of the completion of Phase IIa studies on the drug called TrkA kinase inhibitor are provided. Investors mentioned include Neomed and...

  • RASHES WITH EPIDERMAL CHANGES--I. Buxton, P.K. // British Medical Journal (Clinical Research Edition);11/7/1987, Vol. 295 Issue 6607, p1187 

    Focuses on the clinical features of psoriasis and eczema in Great Britain. Capability of the rashes to change features of the epidermis; Absence of relation between stress and psoriasis; Treatment of skin itching.

  • Clinic Roundup.  // BioWorld Today;3/1/2012, Vol. 23 Issue 41, p5 

    This section offers news briefs on the clinical studies undertaken by pharmaceutical firms. Luxembourg-based Creabilis SA has begun its randomized, double-blind placebo-controlled Phase IIb dose-finding trial of lead product CT327 in psoriasis vulgaris. San Diego, California-based Polaris Group...

  • Clinic Roundup.  // BioWorld Today;3/11/2011, Vol. 22 Issue 48, p5 

    This section offers news briefs on different clinical trials. Cell Therapeutics Inc. has released the final trial design for pixantrone for treatment of B-cell lymphoma. Creabilis SA's Phase IIa trial revealed its psoriasis vulgaris drug CT327 obtained a good effectiveness respnse across several...

  • New Drug Relieves Psoriasis.  // USA Today Magazine;Oct2004, Vol. 133 Issue 2713, p12 

    Announces the availability of the drug efalizumab which could offer relief for people who are suffering from itching, burning skin caused by psoriasis in the U.S. as of October 2004. Percentage of patients suffering from moderate to severe psoriasis who saw their symptoms improve through a...

  • Differential diagnoses - Diagnosing scalp conditions. Stollery, Nigel // GP: General Practitioner;1/6/2014, p5 

    The article offers tips in managing common scalp conditions including Scalp psoriasis, Seborrhoeic dermatitis, and Pityriasis capitis. Topics include the used steroid-based application for scalp diseases treatment, treatment of scalp itching caused by heat, and other conditions associated by...

  • Cobimetinib/pimasertib/vemurafenib.  // Reactions Weekly;1/16/2016, Vol. 1584 Issue 1, p67 

    An abstract is presented for the article "Ocular toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase kinase inhibitors: A case series" by A. Niro and others, published in the "American Journal of Ophthalmology" in the November 2015 issue.

  • Highlights of the Latest Advances in Research on CDK Inhibitors. Cicenas, Jonas; Kalyan, Karthik; Sorokinas, Aleksandras; Jatulyte, Asta; Valiunas, Deividas; Kaupinis, Algirdas; Valius, Mindaugas // Cancers;2014, Vol. 6 Issue 4, p2224 

    Uncontrolled proliferation is the hallmark of cancer and other proliferative disorders and abnormal cell cycle regulation is, therefore, common in these diseases. Cyclin-dependent kinases (CDKs) play a crucial role in the control of the cell cycle and proliferation. These kinases are frequently...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics